







RESEARCH ARTICLE

Antibacterial activity in secondary metabolite extracts of heterotrophic bacteria against *Vibrio alginolyticus*, *Aeromonas hydrophila*, and *Pseudomonas aeruginosa* [version 1; peer review: awaiting peer review]

Jarod Setiaji ^{1,2}, Feli Feliatra ¹, Hilwan Yuda Teruna³, Iesje Lukistyowati¹, Indra Suharman ¹, Zainal Abidin Muchlisin ⁴, Teuku Iskandar Johan²

¹Faculty of Fisheries and Marine Science., Universitas Riau, Pekanbaru, Riau, Indonesia

²Faculty of Agriculture, Universitas Islam Riau, Pekanbaru, Riau, Indonesia

³Faculty of Mathematics and Natural Science, Universitas Riau, Pekanbaru, Riau, Indonesia

⁴Faculty of Marine and Fisheries, Universitas Syiah Kuala, Banda Aceh, Aceh, 23111, Indonesia

V1 First published: 21 Dec 2020, 9:1491
<https://doi.org/10.12688/f1000research.26215.1>

Latest published: 21 Dec 2020, 9:1491
<https://doi.org/10.12688/f1000research.26215.1>

Abstract

Background: Disease causing bacteria such as *Vibrio alginolyticus*, *Aeromonas hydrophila*, and *Pseudomonas aeruginosa* present a problem for fish farming. Treatment to remove them are generally carried out using antibiotics which have side effects on fish, the environment and humans. However, the use of antibacterial compounds derived from heterotrophic bacteria serve as a good alternative for antibiotics. Therefore, this study aimed to explore antibacterial activity in the secondary metabolite extracts of heterotrophic bacteria against *Vibrio alginolyticus*, *Aeromonas hydrophila*, and *Pseudomonas aeruginosa*.

Methods: Heterotrophic bacteria namely *Bacillus* sp. JS04 MT102913.1, *Bacillus toyonensis* JS08 MT102920.1, *Bacillus cereus* JS10 MT102922.1, *Bacillus* sp. JS11 MT102923.1, *Pseudoalteromonas* sp. JS19 MT102924.1, *Bacillus cereus* JS22 MT102926.1, and *Bacillus* sp. strain JS25 MT102927.1 were used in this study. The sequences of these bacteria have been deposited and are available from NCBI GenBank. Each heterotrophic bacterium was cultured on 6L nutrient broth for 8 days, and extracts produced using ethyl acetate to obtain their secondary metabolites. These extracts were tested for their phytochemical contents using FT-IR and also tested for their inhibitory property in pathogenic bacteria by agar diffusion method.

Results: Phytochemical test results showed that the seven heterotrophic bacterial isolates produced terpenoid compounds. Based on the inhibitory test, the secondary metabolite extracts from *Bacillus* sp strain JS04 had the highest inhibitory effect on the growth

Open Peer Review

Reviewer Status AWAITING PEER REVIEW

Any reports and responses or comments on the article can be found at the end of the article.

of pathogenic bacteria namely, *V. alginolyticus* (17.5 mm), *A. hydrophila* (16.8 mm), and *P. aeruginosa* (17.3 mm).

Conclusion: It was concluded that the secondary metabolite extracts of heterotrophic bacteria inhibit the growth of *V. alginolyticus*, *A. hydrophila*, and *P. aeruginosa*.

Keywords

antibacterial, fish pathogens, heterotrophic bacteria, secondary metabolites

Corresponding author: Feli Feliatra (feliatra@yahoo.com)

Author roles: **Setiaji J:** Conceptualization, Data Curation, Formal Analysis, Funding Acquisition, Investigation, Writing – Original Draft Preparation; **Feliatra F:** Conceptualization, Methodology, Project Administration, Supervision, Validation, Writing – Review & Editing; **Teruna HY:** Methodology, Resources, Software, Supervision, Visualization, Writing – Original Draft Preparation; **Lukistyowati I:** Methodology, Supervision, Validation, Writing – Original Draft Preparation; **Suharman I:** Methodology, Software, Supervision, Validation, Visualization; **Muchlisin ZA:** Supervision, Validation, Visualization, Writing – Review & Editing; **Johan TI:** Formal Analysis, Investigation, Methodology, Resources, Software

Competing interests: No competing interests were disclosed.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Copyright: © 2020 Setiaji J *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Data associated with the article are available under the terms of the [Creative Commons Zero "No rights reserved" data waiver](#) (CC0 1.0 Public domain dedication).

How to cite this article: Setiaji J, Feliatra F, Teruna HY *et al.* **Antibacterial activity in secondary metabolite extracts of heterotrophic bacteria against *Vibrio alginolyticus*, *Aeromonas hydrophila*, and *Pseudomonas aeruginosa*** [version 1; peer review: awaiting peer review] F1000Research 2020, 9:1491 <https://doi.org/10.12688/f1000research.26215.1>

First published: 21 Dec 2020, 9:1491 <https://doi.org/10.12688/f1000research.26215.1>

Introduction

Bacteria diseases in fish stocks constitute a major problem for fish farming, since they cause significant economic losses¹⁻³. Common pathogenic bacteria that affect fish include *Vibrio alginolyticus*, *Aeromonas hydrophila* and *Pseudomonas aeruginosa*⁴⁻⁹. *V. alginolyticus* is a gram-negative bacteria which is an opportunistic pathogen in marine animals¹⁰⁻¹³. Bacterial diseases cause different fish infections such as, exophthalmia, ulcers, septicemia, and corneal damage¹⁴⁻¹⁶. *Aeromonas hydrophila* is found to be the main cause of the septicemia epidemic in freshwater fish^{17,18}. Its outbreak causes tissue damage of the spleen, gills, and the fish's stomach¹⁹. *A. hydrophila* is found to frequently infect various fish species namely, catfish (*Ictalurus punctatus*)²⁰, carp (*Cyprinus carpio*) and catfish (*Pangasius hypophthalmus*)²¹, tilapia (*Oreochromis niloticus*)²², salmon (*Oncorhynchus masou masou*)²³, snapper (*Lates calcarifer*)²⁴, striped snakehead (*Channa striata*)²⁵, cod (*Gadus macrocephalus*), and tank goby (*Glossogobius guri*)²⁶. Meanwhile, *P. aeruginosa* is found to infect freshwater and marine fish^{27,28}, with infection being characterized by the expression of red spots due to bleeding, skin darkens, loose scales, protruding eyes, fin erosion²⁹, behavioural changes due to disruption of locomotor activity³⁰, and abnormal swimming³¹.

Bacteria disease treatment is generally carried out using antibiotics, however, these can have adverse effects on the fish and their environment³²⁻³⁷. The accumulation of antibiotics in the fish increase the risk of bacterial resistance^{38,39}. *Escherichia coli* bacteria isolated from the digestive organs of catfish showed high resistance levels towards tetracycline, ampicillin, and chloramphenicol⁴⁰. Therefore, it is necessary to explore natural compounds with antibacterial activity⁴¹. Sea water is a potential source of heterotrophic bacteria that produce antimicrobial compound⁴², and have probiotic activity⁴³.

Sea bacteria such as, *Bacillus* sp. *B. cereus*, *B. toyonensis*, and *Pseudoalteromonas* sp., are known to inhibit the growth of pathogenic bacteria namely, *V. alginolyticus*, *A. hydrophila*, and *Pseudomonas* sp⁴³. They also produce antimicrobial compounds such as, *Pseudoalteromonas*⁴⁴. *Pseudoalteromonas piscicida* produces antimicrobial substances that inhibit the growth of different pathogenic bacteria namely, *Vibrio vulnificus*⁴⁵, *Bacillus* sp⁴⁶, *B. pumilus*⁴⁷, and *B. subtilis*^{48,49}. *Bacillus amyloliquefaciens* shows antibacterial activity towards pathogenic bacteria such as, *Aeromonas hydrophila*, *Vibrio harveyi*, *V. vulnificus*, and *V. parahaemolyticus*⁵⁰. Meanwhile, *Bacillus subtilis* shows antibacterial activity towards the pathogens *Vibrio parahaemolyticus*, *V. vulnificus*, and *Aeromonas hydrophila*⁵¹.

Heterotrophic bacteria extracted from Riau sea waters were examined and found to be able to inhibit the activity of pathogenic bacteria *Aeromonas salmonicida*, *Edwardsiella tarda* and *Edwardsiella ictaluri* previously reported by Setiaji *et al.*⁵². However, the antibacterial activity of these heterotrophic bacteria extracted from Riau sea waters on the pathogenic bacteria namely, *Vibrio alginolyticus*, *Aeromonas hydrophila*, and *Pseudomonas aeruginosa* have never been examined for its

potential against pathogenic bacteria. Therefore, this study aims to explore antibacterial activity in secondary metabolite extracts of heterotrophic bacteria isolated from Riau sea water, against pathogenic bacteria namely, *V. alginolyticus*, *A. hydrophila*, and *P. aeruginosa*.

Methods

Bacterial culture

The heterotrophic bacteria isolates were collected from sea waters in Sungai Pakning Bengkalis Regency Riau Province Indonesia (North latitude 01°21'36,8" and East longitude 102°09'34,1"). 1 liter of the sea water was collected at 50 cm depth by using a water sampler (Tiolan Lab, type: WSV-BIT22), then was transferred into a sample bottle and was put into a cool-box filled with ice at 15°C, before being transported by car for 1 hour to the laboratory. The heterotrophic bacteria was cultured using nutrient Agar (NA; Merck-1.05450.0500). The heterotrophic bacteria cultured were used for an antagonist test against pathogenic bacteria. The antagonist test procedure is as follows, 1 ml of pathogenic inoculants (OD_{600nm} = 0.08–0.1) (OD measured with Thermo scientific, Genesys 10S UV-Vis) was added to 15 ml liquid nutrient Agar media at 50°C, then homogenized, and poured into a petri dish to solidify. Furthermore, Oxytetracycline antibiotic disc paper (Oxoid, CT0041B, OT30 mcg) was used as the positive control, while 30 µl aquades (Kimiapedia id-1720602804) was dripped to a disc paper (Macherey-nagel, MN827 ATD) as the negative control. 30 µl heterotrophic bacterial isolate taken from bacteria culture in nutrient Broth (NB; Merck-1.05443.0500) was dripped to a disc paper and incubated at 30°C for 24 hours. The inhibitory power of heterotrophic bacterial isolate was measured from the diameter of clear zone formed around the disc. From the antagonist test, eight isolates with the best inhibition were collected, and the heterotrophic bacteria was identified using 16S rDNA technique⁴³. The sequenced products were run through BLAST (NCBI Basic Local Alignment Search Tool) and registered to GenBank.

The pathogenic bacteria were obtained from the collection at the Marine Microbiology Laboratory of the Faculty of Fisheries and Marine Science, University of Riau, Indonesia. The heterotrophic and pathogenic bacteria were cultured on the nutrient Agar (NA; Merck-1.05450.0500). The cultured medium was sterilized in an autoclave at a pressure of 15 psi and 121°C for 15 minutes. After 1 hour at room temperature, the medium was inoculated by the heterotrophic bacteria and the pathogenic bacteria. Then the bacteria were incubated in an incubator (Mettler, Model 30–1060) at 30°C for 24 hours.

Isolates test

Previous studies showed that eight heterotrophic bacterial isolates possessed the potential to produce pathogens. Seven of these species were used in this study namely, *Bacillus* sp. JS04 MT102913.1, *Bacillus toyonensis* JS08 MT102920.1, *Bacillus cereus* JS10 MT102922.1, *Bacillus* sp. JS11 MT102923.1, *Pseudoalteromonas* sp. JS19 MT102924.1, *Bacillus cereus* JS22 MT102926.1 and *Bacillus* sp. strain JS25 MT102927.1 have been deposited in GenBank.

Then, each bacterium was cultured in a 6 L nutrient Broth (NB; Merck-1.05443.0500) diluted with sea water of salinity 29 ppt and aerated for 8 days. After this, the bacteria were mixed with ethyl acetate (P.a) at ratio 1:1 and shaken vigorously to homogenize. Subsequent filtering was performed until a clear filtrate was obtained using funnel and filter paper (Whatman 41, no. 1441–125), and evaporated with a rotary evaporator (Cole Parmer, N-1300) at 50°C and a speed of 50 rpm. This allowed thick secondary metabolite extracts to be obtained⁵³.

Phytochemical test and Fourier-transform infrared spectroscopy (FT-IR)

Phytochemical test was conducted on the secondary metabolite extracts of heterotrophic bacteria, which included tests for alkaloid, terpenoid, flavonoid, phenolic, and saponin compounds⁵⁴.

Mayer reagent was prepared by adding 1.36 g HgCl₂ (Merck, 1.04419.0050) to 60 mL distilled water and 5 g Ki (Meck 1.05043.1000) to 10 mL distilled water. Both solutions were then mixed with a further 20 mL distilled water. The Liebermann – burchad reagent was prepared by mixing 97% H₂SO₄ (Merck 1.00731.2500) and 100% CH₃COOH (Merck 1.00063.2500).

Alkaloids were tested for using using 10 mg heterotrophic bacteria extract and 250 µL Mayer reagent.

The terpenoid was tested using 10 mg heterotrophic bacteria extract, 10 drops of CH₃COOH, and 3 drops of H₂SO₄.

Flavonoid tests were performed using 10 mg heterotrophic bacteria extract added to 5 mL distilled water. This was then boiled before adding 0.05 g Mg (Merck 1.05815.1000) and 10 drops of 37% HCl (Merck 1.00317.2500), the mixture was then shaken for one minute.

Phenolic compounds were tested by using 10 mg heterotrophic bacteria extract combined with 500 µL 5% FeCl₃ (Merck 1.03943.0250).

Saponin compounds were tested for using 10 mg heterotrophic bacteria extract added to 5 mL distilled water which was then shaken for 1 minute. 150 µL 1N HCl (Merck 1.00317.2500) was then added, and shaken for another minute.

A positive alkaloid test was indicated by the formation of a white precipitate after adding Mayer reagent. A positive terpenoid test was indicated by the formation of a red colour. A positive flavonoid test was indicated by a red colour change. Phenolic compounds were indicated by a blue colour change. Saponin compounds were indicated by a foam forming.

Meanwhile, to determine the functional groups in secondary metabolite extracts, FT-IR (Shimadzu, IR prestige-21, IR solution software ver. 1.1) spectroscopy analysis was performed. This was conducted by crushing 1 mg of each extract, added to KBr (Merck-1.04950.0500), and mixed vigorously until homogenized. This mixture was then measured for infrared absorbance at 4500–450 cm wavelength.

Inhibitory activity of heterotrophic bacterial extract

The secondary metabolite extracts of heterotrophic bacteria obtained were tested on pathogenic bacteria namely, *V. alginolyticus*, *A. hydrophila*, and *P. aeruginosa* using agar diffusion method, and 6 mm disc paper (Macherey-nagel, MN827 ATD)⁵⁵. The procedure is as follows, 1 ml of pathogenic inoculants (OD_{600nm} = 0.08–0.1) (OD measured with Thermo scientific, Genesys 10S UV-Vis) added to 15 ml liquid nutrient agar media at 50°C, then homogenized, and poured into a petri dish to solidify. Furthermore, Oxytetracycline antibiotic disc paper (Oxoid, CT0041B, OT30 mcg) was used as the positive control, while methanol disc paper was the negative control. The metabolite extracts were then dissolved in 1 mg / mL methanol (P.a) and incubated at 30°C for 24 hours. The inhibitory power of heterotrophic bacterial extracts was measured from the diameter of clear zone formed around the disc.

Data analysis

The data were subjected to one-way analysis of variance followed by the Post Hoc Tukey multiple range test using R 4.0 software (GNU General Public License), *p*<0.05 is considered to indicate a statistically significant difference.

Results

Phytochemical test and functional groups

Phytochemical test results of the metabolite extracts when added to Liebermann-Burchard reagents produced a red colour indicating the presence of terpenoids in the seven isolates. Meanwhile, the test for alkaloid, flavonoid, phenolic, and saponin compounds gave negative results.

Based on infrared spectrum analysis, the secondary metabolite extracts of *Bacillus* sp. strain JS04 contained O-H alcohol, C-H aldehyde, O-H carboxylic acid, and C=C alkene groups. *Bacillus toyonensis* JS08 contained C-H alkanes, C=N nitriles, C=O carbonyl, and C-N amine groups. *Bacillus cereus* JS10 contained C-H alkanes, O-H carboxylic acid, C=C alkenes, and C-H alkanes groups. *Bacillus* sp. JS11 contained O-H alcohol, C-H alkanes, O-H carboxylic acids, and C=O carbonyl groups. *Pseudoalteromonas* sp. JS19 contained alcohol O-H, C-H alkanes, C=O carbonyl, and C=C alkenes groups. *Bacillus cereus* JS22 contain O-H alcohol, C-H alkane, C=O carbonyl, and C=C alkene groups. *Bacillus* sp. JS25 contain C-H alkanes, O-H carboxylic acids, O-H alcohols, and C=C alkenes groups (Table 1⁵⁶).

Inhibitory activity

The results showed that the seven heterotrophic bacterial isolates inhibited the growth of pathogenic bacteria. The extracts inhibitory activity against pathogenic bacteria are shown in Table 2⁵⁶. The average inhibition zone diameter of the extracts against pathogenic bacteria namely, *V. alginolyticus*, *A. hydrophila*, and *P. aeruginosa* ranges from 9.3 to 17.5 mm, 9.3 to 16.8 mm, and 8.5 to 17.3 mm, respectively. This inhibitory zone activity was indicated by the presence of clear zones formed around the disc paper. The largest inhibition zone diameter of the extracts against the growth of pathogenic bacteria was derived from isolates of *Bacillus* sp. strain JS04 (17.5 mm) on

Table 1. Infrared spectrum of secondary metabolite extracts of heterotrophic bacteria.

Secondary metabolite extracts	Spectrum (cm ⁻¹)	Functional groups
<i>Bacillus</i> sp. strain JS04	3148	O-H
	2732	C-H
	2535	O-H
	827	C=C
<i>Bacillus toyonensis</i> strain JS08	2925	C-H
	2361	C=N
	1722	C=O
	1229	C-N
<i>Bacillus cereus</i> strain JS10	2925	C-H
	2735	O-H
	1669	C=C
	1459	C-H
<i>Bacillus</i> sp. strain JS11	3330	O-H
	2925	C-H
	2527	O-H
	1721	C=O
<i>Pseudoalteromonas</i> sp. strain JS19	2930	C-H
	2732	O-H
	1720	C=O
	1455	C-H
<i>Bacillus cereus</i> strain JS22	3567	O-H
	2925	C-H
	1710	C=O
	827	C=C
<i>Bacillus</i> sp. strain JS25	2895	C-H
	2602	O-H
	1364	O-H
	830	C=C

Table 2. Inhibitory activity in the secondary metabolite extracts of heterotrophic bacteria against pathogenic bacteria. Mean values with different superscripts in the same columns were significantly different ($p < 0.05$).

Secondary metabolite extracts	Average of inhibition zone diameter (mm)		
	<i>V. alginolyticus</i>	<i>A. hydrophila</i>	<i>P. aeruginosa</i>
<i>Bacillus</i> sp. strain JS04	17.5 ^a	16.8 ^a	17.3 ^a
<i>Bacillus toyonensis</i> strain JS08	11.0 ^b	9.5 ^b	10.0 ^b
<i>Bacillus cereus</i> strain JS10	10.8 ^b	8.5 ^b	9.5 ^b
<i>Bacillus</i> sp. strain JS11	10.8 ^b	9.0 ^b	9.5 ^b
<i>Pseudoalteromonas</i> sp. strain JS19	10.8 ^b	9.8 ^b	9.8 ^b
<i>Bacillus cereus</i> strain JS22	9.3 ^b	9.3 ^b	8.5 ^b
<i>Bacillus</i> sp. strain JS25	15.8 ^a	15.5 ^a	16.3 ^a

V. alginolyticus, 17.3 mm on *P. aeruginosa*, and 16.8 mm on *A. hydrophila*.

Discussion

Phytochemical test results showed that the seven heterotrophic bacterial isolates produced terpenoids, which consist 5 carbon atoms or isoprene (C5) units. Microbes carry out biosynthesis by producing isopentyl pyrophosphate and dimethyl allyl pyrophosphate for terpenoid formation⁵⁷. A significant relationship between terpenoids gene expression and isoprene production in *Bacillus subtilis* has previously been reported⁵⁸.

Infrared spectrum analysis provided information about the detected compounds in the mixture⁵⁹. Metabolite extracts showed the presence of hydroxyl, aldehyde, carboxylic acid, alkene, alkane, carbonyl, and amine functional groups in these extracts. This indicated that the seven bacterial isolates produced terpenoids, while the functional groups contained in the terpenoids were namely, O-H hydroxyl, C-H aliphatic, carbonyl, C-H cyclic, and carboxylic acid⁶⁰.

The result of inhibitory activity in the secondary metabolite extracts of *Bacillus* sp. strain JS04 showed the largest inhibition zone against the growth of pathogenic bacteria. The formation of clear zones on culture media indicated that heterotrophic bacteria produced terpenoid compounds for antibacterial purposes.

The terpenoid compounds contained several phytochemicals that possess antimicrobial activity⁶¹. For example, Terpenes and terpenoids have been reported to exert antimicrobial activity against a wide variety of bacteria, both Gram-positive and Gram-negative⁶². Terpenes cause membrane disruption through acting on lipophilic compound in the membrane⁶³. Therefore, terpenoid compounds were able to prevent the forming of biofilm cell in the bacterium *Streptococcus mutans*^{60,64}.

There are many antimicrobial compounds produced by sea bacteria especially from the *Bacillus* and *Pseudoalteromonas* genus. For instance, *B. pumilus* produces antimicrobial compound against *V. alginolyticus*, *V. anguillarum*, *Listeria monocytogenes* and *Staphylococcus aureus* pathogens⁴⁸. The *Bacillus* sp. from sea water produced chemical compound

effective at preventing motility of *V. Alginolyticus*⁴⁷. *Bacillus subtilis* produced antibacterial compound against *Aeromonas hydrophila* and *Vibrio parahaemolyticus* pathogens⁴⁹. The genus *Pseudoalteromonas* hosts 16 antimicrobial metabolite producers. To date, a total of 69 antimicrobial compounds are classified into alkaloids, polyketides, and peptides⁴⁵. Furthermore, the bacterium *Pseudoalteromonas rubra* which was symbiotic with soft coral *Sarcophyton* sp. produced carotenoid pigments with antibacterial activity against *Staphylococcus aureus*⁶⁵ and *V. alginolyticus* pathogens⁶⁶.

Conclusion

The secondary metabolite extracts produced by the seven isolates of heterotrophic bacteria can inhibit the growth of pathogenic bacteria, namely *V. alginolyticus*, *A. hydrophila*, and *P. aeruginosa*. The secondary metabolite extracts of *Bacillus* sp. strain JS04 has the highest inhibitory activity against the growth of these three pathogenic bacteria.

Data availability

Underlying data

Figshare: Antibacterial activity in secondary metabolite extracts of heterotrophic bacteria against *Vibrio alginolyticus*, *Aeromonas hydrophila*, and *Pseudomonas aeruginosa* Item. <https://doi.org/10.6084/m9.figshare.12818798.v3>⁵⁶

This project contains the following underlying data:

- Data FT-IR activity in the secondary metabolite. Jarod Setiaji.pdf (Infrared spectrum of secondary metabolite extracts of heterotrophic bacteria)
- Data Inhibitory activity in the secondary metabolite. Jarod Setiaji.xlsx (Inhibitory activity in the secondary metabolite extracts of heterotrophic bacteria against pathogenic bacteria)

Data are available under the terms of the [Creative Commons Attribution 4.0 International license](#) (CC-BY 4.0).

Acknowledgments

The authors are grateful to the laboratory assistants for supporting this research.

References

1. Cai S, Cheng H, Pang H, et al.: **AcfA is an essential regulator for pathogenesis of fish pathogen *Vibrio alginolyticus***. *Vet Microbiol.* 2018; **213**: 35–41. [PubMed Abstract](#) | [Publisher Full Text](#)
2. Liu W, Huang L, Su Y, et al.: **Contributions of the oligopeptide permeases in multistep of *Vibrio alginolyticus* pathogenesis**. *MicrobiologyOpen.* 2017; **6**(5): e00511. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
3. Liu H, Gu D, Cao X, et al.: **Characterization of a new quorum sensing regulator luxT and its roles in the extracellular protease production, motility, and virulence in fish pathogen *Vibrio alginolyticus***. *Arch Microbiol.* 2012; **194**(6): 439–452. [PubMed Abstract](#) | [Publisher Full Text](#)
4. Chen Y, Cai S, Jian J: **Protection against *Vibrio alginolyticus* in pearl gentian grouper (*Epinephelus fuscoguttatus* × *Epinephelus lanceolatus*) immunized**

- with *acfA*-deletion live attenuated vaccine. *Fish Shellfish Immunol.* 2019; **86**: 875–881.
[PubMed Abstract](#) | [Publisher Full Text](#)
5. Zhang D, Moreira GS, Shoemaker C, et al.: **Detection and quantification of virulent *Aeromonas hydrophila* in channel catfish tissues following waterborne challenge.** *FEMS Microbiol Lett.* 2016; **363**(9): fnw080.
[PubMed Abstract](#) | [Publisher Full Text](#)
 6. Stratev D, Odeyemi OA: **Antimicrobial resistance of *Aeromonas hydrophila* isolated from different food sources: A mini-review.** *J Infect Public Health.* 2016; **9**(5): 535–44.
[PubMed Abstract](#) | [Publisher Full Text](#)
 7. Lee J, Zhang L: **The hierarchy quorum sensing network in *Pseudomonas aeruginosa*.** *Protein cell.* 2015; **6**(1): 26–41.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 8. Zheng J, Tang XM, Wu RX, et al.: **Identification and characteristics of aptamers against inactivated *Vibrio alginolyticus*.** *LWT–Food Sci Technol.* 2015; **64**(2): 1138–1142.
[Publisher Full Text](#)
 9. Mittal R, Khandwaha RK, Gupta V, et al.: **Phenotypic characters of urinary isolate of *Pseudomonas aeruginosa* and their association with mouse renal colonization.** *Indian J Med Res.* 2006; **123**(1): 67–72.
[PubMed Abstract](#)
 10. Zhao Z, Liu J, Deng Y, et al.: **The *Vibrio alginolyticus* T3SS effectors, Val1686 and Val1680, induce cell rounding, apoptosis and lysis of fish epithelial cells.** *Virulence.* 2018; **9**(1): 318–330.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 11. Yu Q, Li F, Wang Y, et al.: **Isolation, identification and pathogenicity of *Vibrio alginolyticus* from marine cultured *Trachinotus ovatus* in Beibu Gulf, Guangxi.** *Guangxi Sciences.* 2018; **25**(1): 68–73.
[Reference Source](#)
 12. Cai SH, Lu YS, Jian JC, et al.: **Protection against *Vibrio alginolyticus* in crimson snapper *Lutjanus erythropterus* immunized with a DNA vaccine containing the *ompW* gene.** *Dis Aquat Organ.* 2013; **106**(1): 39–47.
[PubMed Abstract](#) | [Publisher Full Text](#)
 13. Austin B: **Vibrios as causal agents of zoonoses.** *Vet Microbiol.* 2010; **140**(3–4): 310–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
 14. Wang YD, Wang YH, Hui CF, et al.: **Transcriptome analysis of the effect of *Vibrio alginolyticus* infection on the innate immunity-related TLR5-mediated induction of cytokines in *Epinephelus lanceolatus*.** *Fish Shellfish Immunol.* 2016; **52**: 31–43.
[PubMed Abstract](#) | [Publisher Full Text](#)
 15. Luo G, Huang L, Su Y, et al.: ***f1rA*, *f1rB* and *f1rC* regulate adhesion by controlling the expression of critical virulence genes in *Vibrio alginolyticus*.** *Emerg Microbes Infect.* 2016; **5**(8): e85.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 16. Rameshkumar P, Nazar AKA, Pradeep MA, et al.: **Isolation and characterization of pathogenic *Vibrio alginolyticus* from sea cage cultured cobia (*Rachycentron canadum* (Linnaeus 1766)) in India.** *Lett Appl Microbiol.* 2017; **65**(5): 423–430.
[PubMed Abstract](#) | [Publisher Full Text](#)
 17. Xia H, Tang Y, Lu F, et al.: **The effect of *Aeromonas hydrophila* infection on the non specific immunity of blunt snout bream (*Megalobrama amblycephala*).** *Cent Eur J Immunol.* 2017; **42**(3): 239–243.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 18. Chaix G, Roger F, Berthe T, et al.: **Distinct aeromonas populations in water column and associated with Copepods from estuarine environment (Seine, France).** *Front Microbiol.* 2017; **8**: 1259.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 19. Abdelhamed H, Ibrahim I, Baumgartner W, et al.: **Characterization of histopathological and ultrastructural changes in Channel Catfish experimentally infected with virulent *Aeromonas hydrophila*.** *Front Microbiol.* 2017; **8**: 1519.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 20. Jubirt MM, Hanson LA, Hanson-Dorr KC, et al.: **Potential for great egrets (*Ardea alba*) to transmit a virulent strain of *Aeromonas hydrophila* among Channel Catfish (*Ictalurus punctatus*) culture ponds.** *J Wildl Dis.* 2015; **51**(3): 634–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 21. Rasmussen-Ivey CR, Hossain MJ, Odom SE, et al.: **Classification of a hypervirulent *Aeromonas hydrophila* pathotype responsible for epidemic outbreaks in warm-water fishes.** *Front Microbiol.* 2016; **7**: 1615.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 22. Stratev D, Stoev S, Vashin I, et al.: **Some varieties of pathological changes in experimental infection of carps (*Cyprinus carpio*) with *Aeromonas hydrophila*.** *Journal of Aquaculture Engineering and Fisheries Research.* 2015; **1**(4): 191–202.
[Publisher Full Text](#)
 23. Han JE, Kim JH, Choresca C, et al.: **Draft genome sequence of a clinical isolate, *Aeromonas hydrophila* SNUFPC-A8, from a Moribund Cherry Salmon (*Oncorhynchus masou masou*).** *Genome Announc.* 2013; **1**(1): e00133–12.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 24. Hamid R, Ahmad A, Usup G: **Pathogenicity of *Aeromonas hydrophila* isolated from the Malaysian Sea against coral (*Turbinariasp*) and seabass (*Lates calcarifer*).** *Environ Sci Pollut Res Int.* 2016; **23**(17): 17269–76.
[PubMed Abstract](#) | [Publisher Full Text](#)
 25. Samayanpaulraj V, Sivaramapillai M, Palani SN, et al.: **Identification and characterization of virulent *Aeromonas hydrophila* Ah17 from infected *Channa striata* in river Cauvery and in vitro evaluation of shrimp chitosan.** *Food Sci Nutr.* 2020; **8**(2): 1272–1283.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 26. Citterio B, Biavasco F: ***Aeromonas hydrophila* virulence.** *Virulence.* 2015; **6**(5): 417–418.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 27. Mishra P, Jerobin SRSJ, Thomas J, et al.: **Study on antimicrobial potential of neem oil nanoemulsion against *Pseudomonas aeruginosa* infection in *Labeo rohita*.** *Biotechnol Appl Biochem.* 2014; **61**(5): 611–619.
[PubMed Abstract](#) | [Publisher Full Text](#)
 28. Thomas J, Thanigaivel S, Vijayakumar S, et al.: **Pathogenicity of *Pseudomonas aeruginosa* in *Oreochromis mossambicus* and treatment using lime oil nanoemulsion.** *Colloids Surf B Biointerfaces.* 2014; **116**: 372–377.
[PubMed Abstract](#) | [Publisher Full Text](#)
 29. Altinok I, Kayis S, Capkin E: ***Pseudomonas putida* infection in rainbow trout.** *Aquaculture.* 2006; **261**(3): 850–855.
[Publisher Full Text](#)
 30. Baldissera MD, Souza CF, Santos RCV, et al.: ***Pseudomonas aeruginosa* strain PAO1 infection impairs locomotor activity in experimentally infected *Rhamdia quelen*: Interplay between a stress response and brain neurotransmitters.** *Aquaculture.* 2017a; **473**: 74–79.
[Publisher Full Text](#)
 31. Baldissera MD, Souza CF, Santos RCV, et al.: **Blood brain barrier breakdown and myeloperoxidase activity in silver catfish experimentally infected with *Pseudomonas aeruginosa*.** *J Fish Dis.* 2018; **41**(2): 209–213.
[PubMed Abstract](#) | [Publisher Full Text](#)
 32. Rodriguez-Mozaz S, Vaz-Moreira I, Giustina SVD, et al.: **Antibiotic residues in final effluents of European wastewater treatment plants and their impact on the aquatic environment.** *Environ Int.* 2020; **140**: 105733.
[PubMed Abstract](#) | [Publisher Full Text](#)
 33. Cao J, Zhang J, Ma L, et al.: **Identification of fish source *Vibrio alginolyticus* and evaluation of its bacterial ghosts vaccine immune effects.** *Microbiologyopen.* 2018; **7**(3): e00576.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 34. Chuah LO, Effarizah ME, Goni AM, et al.: **Antibiotic Application and Emergence of Multiple Antibiotic Resistance (MAR) in Global Catfish Aquaculture.** *Curr Environ Health Rep.* 2016; **3**(2): 118–127.
[PubMed Abstract](#) | [Publisher Full Text](#)
 35. Di Cesare A, Luna GM, Vignaroli C, et al.: **Aquaculture can promote the presence and spread of antibiotic-resistant enterococci in marine sediments.** *PLoS One.* 2013; **8**(4): e62838.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 36. Romero J, Gloria C, Navarrete P: **Antibiotics in aquaculture-use, abuse and alternatives.** *Health and Environment in Aquaculture.* 2012; 159–202.
[Publisher Full Text](#)
 37. Ding C, He J: **Effect of antibiotics in the environment on microbial populations.** *Appl Microbiol Biotechnol.* 2010; **87**(3): 925–41.
[PubMed Abstract](#) | [Publisher Full Text](#)
 38. Rasul MG, Majumdar BC: **Abuse of antibiotics in aquaculture and its effects on human, aquatic animal and environment.** *The Saudi Journal of Life Sciences.* 2017; **2**(3): 81–88.
[Publisher Full Text](#)
 39. Olesen I, Hasman H, Aarestrup MF: **Prevalence of β -Lactamases among ampicillin-resistant *Escherichia coli* and *Salmonella* isolated from food animals in denmark.** *Microb Drug Resist.* 2004; **10**(4): 334–340.
[PubMed Abstract](#) | [Publisher Full Text](#)
 40. Damayanti S, Kusdarwati R, Suprpto H: **Bacterial resistance of *Escherichia coli* against antibiotics in *Clarias batrachus* digestion.** *AACL Bioflux.* 2019; **12**(6): 2195–2201.
[Reference Source](#)
 41. Samuel L, Marian MM, Apun K, et al.: **Characterization of *Escherichia coli* isolated from cultured catfish by antibiotic resistance and RAPD analysis.** *Int Food Res J.* 2011; **18**(3): 971–976.
[Reference Source](#)
 42. Alekseeva BI, Danilovich KA, Valirievna KU: **Antimicrobial Activity of Heterotrophic Bacterial Strains of Marine Origin.** *Undishapur Journal of Microbiology.* 2013; **6**(2): 166–175.
[Publisher Full Text](#)
 43. Setiaji J: **DNA Analysis of marine heterotrophic bacteria that are antagonistic towards pathogenic bacteria in fish.** *Proceedings of the 18th National Ocean Seminar.* Implementation of marine and coastal resources research results in the framework of achieving national economic independence. Faculty of Engineering and Marine Sciences, Universitas Hang Tuah, Surabaya, Indonesia. 2018; c2.17-27. [In Indonesian].
 44. Offret C, Desriac F, Le Chevalier P, et al.: **Spotlight on antimicrobial metabolites from the marine bacteria *Pseudoalteromonas*: chemodiversity and ecological significance.** *Mar Drugs.* 2016; **14**(7): 129.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

45. Richards GP, Needleman DS, Watson MA, *et al.*: **Whole-Genome Sequences of Two *Pseudoalteromonas piscicida* Strains, DE1-A and DE2-A, with Strong Antibacterial Activity against *Vibrio vulnificus*.** *Microbiol Resour Announc.* 2019; **8**(1): e01451-18.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
46. Xiu P, Liu R, Zhang D, *et al.*: **Pumilacidin-Like Lipopeptides Derived from Marine Bacterium *Bacillus* sp. Strain 176 Suppress the Motility of *Vibrio alginolyticus*.** *Appl Environ Microbiol.* 2017; **83**(12): e00450-17.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
47. Zidour M, Chevalier M, Belguesmia Y, *et al.*: **Isolation and Characterization of Bacteria Colonizing *Acartia tonsa* Copepod Eggs and Displaying Antagonist Effects against *Vibrio anguillarum*, *Vibrio alginolyticus* and Other Pathogenic Strains.** *Front Microbiol.* 2017; **8**: 1919.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
48. Chakraborty K, Thilakan B, Raola VK: **Polyketide family of novel antibacterial 7-O-methyl-5'-hydroxy-3'-heptenoate-macrolactin from seaweed-associated *Bacillus subtilis* MTCC 10403.** *J Agric Food Chem.* 2014; **62**(50): 12194-12208.
[PubMed Abstract](#) | [Publisher Full Text](#)
49. Li W, Tang XX, Yan X, *et al.*: **A new macrolactin antibiotic from deep sea-derived bacteria *Bacillus subtilis* B5.** *Nat Prod Res.* 2016; **30**(24): 2777-2782.
[PubMed Abstract](#) | [Publisher Full Text](#)
50. Chakraborty K, Thilakan B, Raola VK: **Previously Undescribed Antibacterial Polyketides from Heterotrophic *Bacillus amyloliquefaciens* Associated with Seaweed *Padina gymnospora*.** *Appl Biochem Biotechnol.* 2017a; **184**(2): 716-732.
[PubMed Abstract](#) | [Publisher Full Text](#)
51. Chakraborty K, Thilakan B, Raola VK: **Antimicrobial polyketide furanoterpenoids from seaweed-associated heterotrophic bacterium *Bacillus subtilis* MTCC 10403.** *Phytochemistry.* 2017b; **142**: 112-125.
[PubMed Abstract](#) | [Publisher Full Text](#)
52. Setiaji J, Feliatra F, Teruna HY, *et al.*: **Antimicrobial agents derived from heterotrophic bacteria against pathogenic bacteria.** *IOP Conf Ser Earth Environ Sci.* 2019; **348**: 012029.
[Reference Source](#)
53. Sateesh VN, Rathod JL: **Selective isolation and antimicrobial activity of rare actinomycetes from mangrove sediment of Karwar.** *Journal of Ecobiotechnology.* 2011; **3**(10): 48-53.
[Reference Source](#)
54. Devi GK, Manivannan K, Thirumaran G, *et al.*: ***In vitro* antioxidant activities of selected seaweeds from Southeast coast of India.** *Asian Pac J Trop Med.* 2011; **4**(3): 205-211.
[PubMed Abstract](#) | [Publisher Full Text](#)
55. Feliatra, Muchlisin ZA, Teruna HY, *et al.*: **Potential of bacteriocins produced by probiotic bacteria isolated from tiger shrimp and prawns as antibacterial to *Vibrio*, *Pseudomonas*, and *Aeromonas* species on fish [version 1; peer review: 2 approved, 1 approved with reservations, 1 not approved].** *F1000Res.* 2018; **7**: 415.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
56. Muchlisin ZA, Setiaji J, Feliatra F, *et al.*: **Antibacterial activity in secondary metabolite extracts of heterotrophic bacteria against *Vibrio alginolyticus*, *Aeromonas hydrophila*, and *Pseudomonas aeruginosa* Item.** *figshare.* Dataset. 2020.
<http://www.doi.org/10.6084/m9.figshare.12818798.v3>
57. Moser S, Pichler H: **Identifying and engineering the ideal microbial terpenoid production host.** *Appl Microbiol Biotechnol.* 2019; **103**(14): 5501-5516.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
58. Hess BM, Xue J, Markillie LM, *et al.*: **Coregulation of Terpenoid Pathway Genes and Prediction of Isoprene Production in *Bacillus subtilis* Using Transcriptomics.** *PLoS One.* 2013; **8**(6): e66104.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
59. Krishna GM, Muthukumar M, Krishnamoorthy B, *et al.*: **A Critical review on fundamental and pharmaceutical analysis of FT-IR spectroscopy.** *Int J Pharm.* 2013; **3**(2): 396-402.
[Reference Source](#)
60. Widyawati, Yanwirasti, Djong DH, *et al.*: **Potential of terpenoid isolated from *Myrmecodia pendans* AS antibacterial against *Streptococcus mutans* ATCC 2517.** *International Journal of Development Research.* 2016; **6**(11): 10350-10354.
[Reference Source](#)
61. Barbieri R, Coppo E, Marchese A, *et al.*: **Phytochemicals for human disease: An update on plant-derived compounds antibacterial activity.** *Microbiol Res.* 2017; **196**: 44-68.
[PubMed Abstract](#) | [Publisher Full Text](#)
62. Mahizan NA, Yang SK, Moo CL, *et al.*: **Terpene Derivatives as a Potential Agent against Antimicrobial Resistance (AMR) Pathogens.** *Molecules.* 2019; **24**(14): 2631.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
63. Cowan MM: **Plant products as antimicrobial agents.** *Clin Microbiol Rev.* 1999; **12**(4): 564-582.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
64. Gartika M, Pramesti HT, Kurnia D, *et al.*: **A terpenoid isolated from sarang semut (*Myrmecodia pendans*) bulb and its potential for the inhibition and eradication of *Streptococcus mutans* biofilm.** *BMC Complement Altern Med.* 2018; **18**(1): 151.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
65. Wiguna AS, Kusmita L, Radjasa OK: **Antibacterial activity test of carotenoid pigments from soft coral symbiont isolates from *Sarcophyton* sp. on the growth of *Staphylococcus aureus* ATCC 25923 bacteria.** *Indonesian Journal of Pharmaceutical Science and Technology.* 2016; **3**(3): 92-98. [In Indonesian].
[Publisher Full Text](#)
66. Supardy NA, Ibrahim D, Nor SRM, *et al.*: **Bioactive Compounds of *Pseudoalteromonas* sp. IBRL PD4.8 Inhibit Growth of Fouling Bacteria and Attenuate Biofilms of *Vibrio alginolyticus* FB3.** *Pol J Microbiol.* 2019; **68**(1): 21-33.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research